Filing Analysis
Microbot Medical announced the full market release of its LIBERTY Endovascular Robotic System and reported securing new accounts following the Society of Interventional Radiology annual meeting. The company highlighted that two of these new accounts were previous participants in its ACCESS-PVI pivotal clinical trial.
Key Facts
- Commencement of the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System.
- Reported strong interest from physicians and hospital executives at the Society of Interventional Radiology (SIR) annual meeting.
- Successfully won accounts in key sales territories.
- Two new accounts were former participants in the Company’s ACCESS-PVI pivotal clinical trial.
- The filing is a Regulation FD disclosure under Item 7.01.
Microbot Medical Inc. announced the appointment of Alon Tamir as Vice President of Sales for the EMEA region to lead international expansion. The company is focusing on the commercial rollout of its LIBERTY Endovascular Robotic System in Europe, the Middle East, and Asia.
Key Facts
- Appointment of Alon Tamir as VP of Sales, EMEA, effective April 30, 2026.
- The role focuses on developing go-to-market strategies and distribution partnerships in Europe, the Middle East, and Asia.
- The company continues to prioritize its U.S. commercial efforts while building international regulatory and operational capabilities.
- The expansion leverages the commercial launch of the LIBERTY Endovascular Robotic System.
Microbot Medical Inc. announced that new joint safety guidelines from major interventional radiology societies (SIR and CIRSE) regarding occupational protection may enhance the commercial adoption of its LIBERTY Endovascular Robotic System.
Key Facts
- The Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) released updated joint guidelines on April 22, 2026.
- The guidelines provide safety guidance for physicians, radiographers, and nurses involved in interventional radiology procedures.
- The Company believes these guidelines strengthen the commercial position of its LIBERTY Endovascular Robotic System, which likely offers radiation protection benefits.
- The information was furnished under Item 7.01 and is not deemed 'filed' for regulatory purposes.
Microbot Medical Inc. announced that its CEO, Harel Gadot, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The presentation will focus on the recent Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System and the company's commercial growth strategy.
Key Facts
- CEO Harel Gadot is scheduled to present live at 10:15 a.m. ET on Wednesday, April 15, 2026.
- The presentation will highlight the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System.
- Management intends to discuss strategic positioning regarding physician radiation risks, physical strain, and healthcare staffing issues.
- The filing includes a press release furnished as Exhibit 99.1.
Microbot Medical announced the full U.S. market release of its LIBERTY Endovascular Robotic System following a successful limited release phase. The company is aggressively expanding its commercial footprint, doubling its sales territories from four to eight with a target of twelve by the end of 2026.
Key Facts
- Full U.S. market release of LIBERTY® Endovascular Robotic System announced on April 13, 2026.
- The system has been adopted by major healthcare providers including Emory Healthcare and Tampa General Hospital.
- Successful commercial use reported in procedures such as Prostate Artery Embolization (PAE) and Y90 deliveries.
- Sales force expansion from 4 to 8 territories currently, with a goal of 12 territories by year-end 2026.
Microbot Medical Inc. has filed a prospectus supplement to its existing shelf registration statement to launch an 'at the market' (ATM) offering program for up to $39,230,691 of its common stock. The offering will be conducted through H.C. Wainwright & Co., LLC as the sales agent.
Red Flags
- Potential for significant shareholder dilution, especially common in micro-cap companies using ATM facilities.
- Continuous reliance on equity financing to fund operations.
Key Facts
- The company may sell up to $39,230,691 in common stock through an ATM program.
- H.C. Wainwright & Co., LLC is acting as the sales agent.
- The offering is based on an At the Market Offering Agreement dated June 10, 2021, as amended on July 1, 2024.
- Sales will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-275634).
- Transactions will be made at market prices prevailing at the time of sale on the Nasdaq Capital Market.
Microbot Medical announced the successful completion of robotic peripheral endovascular procedures at Emory Healthcare using its LIBERTY® Endovascular Robotic System. The procedures successfully targeted benign prostatic hyperplasia (BPH) and liver cancer, marking a clinical milestone for the company's technology.
Key Facts
- Joint press release issued with Emory Healthcare on March 26, 2026.
- Emory interventional radiologists successfully used the LIBERTY® Endovascular Robotic System for minimally invasive treatments.
- Clinical applications demonstrated include benign prostatic hyperplasia (BPH) and liver cancer.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. announced the publication of a peer-reviewed article in the Journal of Vascular and Interventional Radiology (JVIR) regarding its disposable endovascular robotic system. The study focused on the feasibility of the system for arterial peripheral vascular interventions.
Key Facts
- The article is titled 'In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.'
- The lead author, Dr. Francois Cornelis, is the Lead Principal Investigator for the LIBERTY ACCESS PVI Pivotal Study.
- The filing was made under Item 7.01 (Regulation FD Disclosure) on March 24, 2026.
- The publication provides clinical validation for the company's robotic technology in a multicenter setting.
Microbot Medical Inc. announced its participation in the Roth Annual Growth Conference scheduled for March 22-24, 2026. The company's CEO, Harel Gadot, will present a fireside Q&A and the company has released updated investor presentation materials.
Key Facts
- Participation in the Roth Annual Growth Conference in Laguna Niguel, CA, from March 22-24, 2026.
- CEO Harel Gadot will present a live fireside Q&A on March 23, 2026, at 4:00 pm PT.
- Updated investor presentation materials were released as Exhibit 99.2.
- The information is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Microbot Medical Inc. announced its scheduled participation in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. CEO Harel Gadot is set to deliver a live presentation on March 19, 2026.
Key Facts
- The company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference held March 16-19, 2026.
- CEO, President, and Chairman Harel Gadot will present live on March 19, 2026, at 8:40 am ET.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure).
- A press release regarding the event was furnished as Exhibit 99.1.
Microbot Medical issued a press release on March 4, 2026, commending the American Medical Association's (AMA) efforts to protect healthcare professionals from ionizing radiation. The filing is a standard Regulation FD disclosure and does not report material financial or operational changes.
Key Facts
- The report was filed on March 4, 2026, under Item 7.01.
- The company expressed support for AMA initiatives regarding ionizing radiation protection for healthcare workers.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Exhibit 99.1 contains the full text of the press release.
Microbot Medical Inc. issued a press release on March 3, 2026, confirming its operational and commercial stability despite ongoing geopolitical events in the Middle East. The disclosure was made under Item 7.01 to provide a status update to investors regarding business continuity.
Red Flags
- Implicit exposure to geopolitical risk in the Middle East, which necessitated a public reassurance of stability.
Key Facts
- The report was filed on March 3, 2026, under Item 7.01 (Regulation FD Disclosure).
- The company confirmed 'continued operational and commercial stability' in the face of Middle East geopolitical events.
- The information was furnished via Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act.
- The filing was signed by Harel Gadot, CEO, President, and Chairman.
Microbot Medical Inc. entered into amended employment agreements with its CTO, CFO, and CMO, providing for salary increases and higher bonus potentials. The company also authorized a one-time special bonus of $140,000 for CEO Harel Gadot.
Key Facts
- CTO Simon Sharon's annual base salary increased to NIS 1,008,000 (approx. $276,000 USD) with a maximum bonus of 50% of base salary.
- CFO Rachel Vaknin's annual base salary increased to NIS 756,000 (approx. $207,000 USD) with a maximum bonus of 50% of base salary.
- CMO Juan Diaz-Cartelle's maximum annual bonus was increased to 50% of base salary.
- CEO Harel Gadot was awarded a special bonus of approximately $140,000, effective February 18, 2026.
- Salary reviews for the CTO and CFO will now be conducted annually by the Compensation Committee based on performance metrics without requiring further formal amendments.
Microbot Medical Inc. announced that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System. This commercial milestone follows the company's recent FDA 510(k) clearance for the device.
Key Facts
- Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System.
- The adoption follows the company's recent FDA 510(k) clearance for the system.
- The announcement was made via a press release on February 24, 2026.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure).
Microbot Medical Inc. filed a routine Regulation FD disclosure announcing that CEO Harel Gadot will participate as a panelist at The Surgical Disruptive Technology Summit, part of the SAGES NBT Innovation Weekend, held February 19-21, 2026 in Houston, TX. No material business developments were disclosed.
Red Flags
- CEO serves as both President and Chairman, concentrating governance authority — though common for micro-caps, it reduces board independence
Key Facts
- CEO Harel Gadot is a featured panelist at The Surgical Disruptive Technology Summit (SAGES NBT Innovation Weekend)
- Conference held February 19-21, 2026 in Houston, TX
- Information is 'furnished' under Item 7.01, not 'filed' — standard Reg FD treatment with no Section 18 liability
- Company is listed on NASDAQ Capital Market under ticker MBOT
- Harel Gadot holds triple role: CEO, President, and Chairman of the Board